Caracemide - ≥95.0%, high purity , CAS No.81424-67-1

Item Number

C646316

• Specifications & Purity: ≥95%
• Biochemical and Physiological Mechanisms: Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads

Product Description

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity.

In Vitro

Caracemide inactivates R1 by covalent modification at the substrate-binding site and has a toxic metabolite, methylisocyanate (MIC), in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The mercapturic acid derivative AMCC was identified in urine rats following administration to rats of a single i.p. dose (6.6 mg/kg) of caracemide (NSC-253272) . . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid